Therapy related acute myeloid leukemia and myelodysplastic syndrome
MONDO:0019457An acute myeloid leukemia secondary to a myelodysplastic syndrome or therapy-related. (WHO, 2001)
Also known as: Secondary AGL, Secondary Acute granulocytic Leukaemia, Secondary Acute granulocytic Leukemia, Secondary Acute myeloblastic Leukaemia, Secondary Acute myeloblastic Leukemia, Secondary Acute myelocytic Leukaemia, Secondary Acute myelocytic Leukemia, Secondary Acute myelogenous Leukaemia
3174 clinical trials for this condition and its sub-types, 87 tagged with Therapy related acute myeloid leukemia and myelodysplastic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Therapy related acute myeloid leukemia and myelodysplastic syndrome
-
Experimental combo for tough leukemia shows promise in early trial
Disease control Stopped earlyThis pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. …
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Experimental combo for resistant leukemia shows early promise but trial halted
Disease control Stopped earlyThis pilot study tested a new drug called sEphB4-HSA combined with standard chemotherapy (azacitidine or decitabine) in 7 patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia that had returned or not responded to prior treatment. The …
Phase 2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising combo for tough leukemias hits snag: trial ends early
Disease control Stopped earlyThis phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental combo for tough leukemias shows early promise
Disease control Stopped earlyThis early-phase study tested two drugs, AZD1775 and belinostat, together in 20 adults with blood cancers like acute myeloid leukemia that had come back or not responded to treatment. The main goal was to find the safest dose and understand side effects. The study was stopped ear…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental drug tested for Tough-to-Treat leukemia, but study stopped early
Disease control Stopped earlyThis phase 2 trial tested a drug called PF-05212384 in 10 people with certain types of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including cases linked to past cancer treatment or that had come back after other therapies. The drug was given weekly through an…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 26, 2026 14:44 UTC